Evelyne Bischof, Chaim Haber, Niklas Lidströmer
Shanghai University of Medicine and Health Sciences. Sheba Medical Center, Grey School of Medicine and Tel Aviv University. University of Copenhagen. Karolinska Institutet.
China, Israel, Denmark and Sweden
Heart Failure Clinics
Heart Fail Clin 2026; 22: 361-370
DOI: 10.1016/j.hfc.2026.02.009
Abstract
Pulmonary hypertension (PH) is a severe and oftentimes fatal disease with a high degree of clinical variability. Its complexity necessitates a multifaceted approach, with clinical and prognostic results significantly improved with earlier identification and initiation of treatment. Developments in artificial intelligence (AI) and machine learning (ML) allow earlier diagnosis, individualized treatments, and new therapeutic options, which have already shown real potential to improve patient outcomes; such an intricate approach was not feasible before the AI innovations of the last decade. This article outlines the current applications of AI and ML for diagnostics, treatment optimization, surveillance, and drug discovery for PH.
Category
Mechanical and Computer Models of Pulmonary Vascular Disease and Therapy
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease or Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No